Cerenome, Inc. (CNSY)
| Market Cap | 12.14M -82.0% |
| Revenue (ttm) | 4.20M -21.0% |
| Net Income | -26.09M |
| EPS | -4.37 |
| Shares Out | 7.59M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 234,618 |
| Open | 1.810 |
| Previous Close | 1.780 |
| Day's Range | 1.540 - 1.860 |
| 52-Week Range | 1.540 - 23.425 |
| Beta | 1.47 |
| Analysts | Strong Buy |
| Price Target | 32.50 (+1,931.25%) |
| Est. Earnings | Oct 29, 2026 |
About CNSY
Cerenome, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company’s lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary li... [Read more]
Financial Performance
In 2025, Cerenome's revenue was $5.21 million, a decrease of -10.49% compared to the previous year's $5.82 million. Losses were -$22.39 million, 72.5% more than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for CNSY stock is "Strong Buy." The 12-month stock price target is $32.5, which is an increase of 1,931.25% from the latest price.
News
Cerenome Slides: Investor presentation
Cerenome has posted slides in relation to its latest quarterly earnings report, which was published on October 2, 2026.
Cerenome price target lowered to $31 from $50 at Lake Street
Lake Street lowered the firm’s price target on Cerenome (CNSY) to $31 from $50 and keeps a Buy rating on the shares. The firm’s revised price target reflects updated CNSide…
Cerenome Transcript: Investor update
CNSide achieved 158 million covered lives and began billing, with Medicare rates expected in early 2027. Test volumes and menu expansion are on track, and gross billings reached $1.55 million on 222 tests. Annualized run rate is projected at $10–12.5 million, with cash runway into 2028.
Cerenome Press release: Investor update
Cerenome issued a press release on September 30, 2026, disclosing material business information to investors.
Cerenome Expects $1.55 Million in CNSide® Third Quarter Gross Billings
Lead test on track for 200 million covered lives and beneficiaries by early 2027 after CMS meeting On track to launch expanded CNSide testing menu with multiple tests in Q4 2026 HOUSTON, Sept. 30, 202...
Cerenome to Hold CNSide® Business Update Call on September 30, 2026
HOUSTON, Sept. 25, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), today announced that management will h...
Cerenome Secures In-Network Agreement with Blue Cross Blue Shield of Michigan, Expanding CNSide® Contracted Coverage to Approximately 158 Million Covered Lives
HOUSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), announced today that it has signed an ...
Cerenome Appoints Samantha Fowlkes as Vice President and Head of Commercial Sales, CNSide Diagnostics Division
HOUSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), today announces the appointment of Samant...
Cerenome Announces Up to $20 Million Financing Facility with Royalty-Based Repayment
Capital will support continued CNSide® commercial scale-up and development Initial tranche of funding provided at closing with future tranches linked to milestones Forecasted cash runway now into 2028...
Cerenome Highlights Presentations at the 2026 SNO/ASCO CNS Metastases Conference Demonstrating Progress in Both Therapeutics and Diagnostics Business Lines
Cerenome highlights SNO/ASCO data showing REYOBIQ CSF distribution and safety, and CNSide's potential to reduce monthly LM treatment costs by up to 47%.
Cerenome Reports Second Quarter 2026 Financial Results and Business Update
HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), a CNS oncology company advancing an integrated platform that combines precision diagnostics, tar...
Cerenome Quarterly report: Q2 2026
Cerenome has published its Q2 2026 quarterly earnings report on August 14, 2026.
Cerenome Earnings release: Q2 2026
Cerenome released its Q2 2026 earnings on August 14, 2026, summarizing the period's financial results.
Cerenome Secures In-Network Agreement with Health Care Service Corporation, Expanding CNSide® Contracted Coverage to Over 150 Million Covered Lives
HOUSTON, Aug. 13, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), announced today that it has signed an in-n...
Cerenome Launches as an Integrated CNS Oncology Company
HOUSTON, July 31, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), today announces that its corporate rebrand to Cerenome will be completed as scheduled. Effective Augu...
Plus Therapeutics Announces Scientific Presentations and Sponsored Symposium at 2026 SNO/ASCO CNS Metastases Conference
HOUSTON, July 28, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a healthcare company developing and commercializing targeted therapeutics and diagnostics for central...
Plus Therapeutics Secures Regional Coverage Agreement with Medical Mutual for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
HOUSTON, July 21, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), announced today that it has signe...
Plus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide® CSF Assay Platform
Collaboration expected to deliver hundreds of DNA and RNA biomarkers from a single CSF specimen — directly aligned with the updated NCCN Guidelines® (Version 2.2026), which now recognize CSF circulati...
Plus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide® in Leptomeningeal Metastases Monitoring
Updated NCCN language continues to support CSF analysis in the diagnosis and management of leptomeningeal metastases, including CSF cytology follow-up every 4 to 8 weeks for patients receiving intrath...
Plus Therapeutics Provides Mid-Year Business Update Including Corporate Rebranding
Plus Therapeutics to become Cerenome, to trade under new Nasdaq ticker CNSY on August 3, 2026 Affirms 2026 guidance on key milestones Reports positive CNSide® commercial progress HOUSTON, June 30, 202...
Plus Therapeutics Secures National Coverage Agreement with Elevance Health for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
HOUSTON, June 25, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), announced today that it has signed a ...
Plus Therapeutics to Provide Business Update Call on June 30, 2026
Management to update on 2026 mid-year progress, milestones and provide details on its integrated CNS oncology strategy and artificial intelligence plans Management to update on 2026 mid-year progress,...
Plus Therapeutics Announces CAP Accreditation of CNSide® Diagnostics Clinical Laboratory
HOUSTON, June 04, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company advancing precis...
Plus' CNSide Diagnostic Platform Demonstrates Substantial Healthcare Cost Reduction in Patients with Leptomeningeal Metastases
Plus and Harvard analysis shows CNSide enables early diagnosis and better clinical decision-making reducing healthcare costs by 40%
Plus Therapeutics Partners with Ephemeral Technologies to Deploy AI Execution Platform for CNS Oncology
Partnership to deliver a novel AI-native integrated CNS oncology platform Platform will unify and analyze Plus' proprietary therapeutic, diagnostic, and bioinformatics datasets to accelerate precision...